These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

726 related items for PubMed ID: 26486925

  • 1. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
    Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF.
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
    [Abstract] [Full Text] [Related]

  • 2. Management of vascular Behçet's disease.
    Alibaz-Oner F, Direskeneli H.
    Int J Rheum Dis; 2019 Jan; 22 Suppl 1():105-108. PubMed ID: 29665281
    [Abstract] [Full Text] [Related]

  • 3. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [Abstract] [Full Text] [Related]

  • 4. Thalidomide in Behçet's disease.
    Shek LP, Lim DL.
    Biomed Pharmacother; 2002 Feb; 56(1):31-5. PubMed ID: 11908493
    [Abstract] [Full Text] [Related]

  • 5. Systemic vasculitis and the gut.
    Hatemi I, Hatemi G, Çelik AF.
    Curr Opin Rheumatol; 2017 Jan; 29(1):33-38. PubMed ID: 27684357
    [Abstract] [Full Text] [Related]

  • 6. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
    Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL.
    Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
    [Abstract] [Full Text] [Related]

  • 7. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
    Hu YC, Yang YH, Lin YT, Wang LC, Yu HH, Lee JH, Chiang BL.
    BMC Pediatr; 2019 Jul 11; 19(1):232. PubMed ID: 31296171
    [Abstract] [Full Text] [Related]

  • 8. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
    Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K, Tektonidou M, Markomichelakis N.
    Arthritis Rheumatol; 2017 Dec 11; 69(12):2380-2385. PubMed ID: 28834393
    [Abstract] [Full Text] [Related]

  • 9. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N, Mizoshita T, Sugiyama T, Togawa S, Miyaki T, Suzuki T, Tanida S, Kataoka H, Sasaki M.
    Dig Liver Dis; 2019 Jul 11; 51(7):967-971. PubMed ID: 30872086
    [Abstract] [Full Text] [Related]

  • 10. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
    Byeon JS, Choi EK, Heo NY, Hong SC, Myung SJ, Yang SK, Kim JH, Song JK, Yoo B, Yu CS.
    Dis Colon Rectum; 2007 May 11; 50(5):672-6. PubMed ID: 17216141
    [Abstract] [Full Text] [Related]

  • 11. Thalidomide responsiveness in an infant with Behçet's syndrome.
    Shek LP, Lee YS, Lee BW, Lehman TJ.
    Pediatrics; 1999 Jun 11; 103(6 Pt 1):1295-7. PubMed ID: 10353947
    [Abstract] [Full Text] [Related]

  • 12. Switching of anti-TNF-α agents in Behçet's disease.
    Furuta S, Chow YW, Chaudhry AN, Jayne D.
    Clin Exp Rheumatol; 2012 Jun 11; 30(3 Suppl 72):S62-8. PubMed ID: 23010387
    [Abstract] [Full Text] [Related]

  • 13. Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet's Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center.
    Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF.
    Medicine (Baltimore); 2016 Apr 11; 95(16):e3348. PubMed ID: 27100417
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
    Li L, Liu JJ, Yu X, Wu D, Zhang SZ, Yang YJ, Zhou JX, Zeng XF, Zhang FC, Zheng WJ.
    Zhonghua Nei Ke Za Zhi; 2020 Apr 01; 59(4):303-308. PubMed ID: 32209197
    [Abstract] [Full Text] [Related]

  • 15. Sucessful use of thalidomide in severe gastrointestinal Behçet's disease.
    Lim YK, Keating JP, Steele R.
    ANZ J Surg; 2015 Jun 01; 85(6):496. PubMed ID: 26031928
    [No Abstract] [Full Text] [Related]

  • 16. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
    Zlatanović G, Jovanović S, Veselinović D, Zivković M.
    Vojnosanit Pregl; 2012 Feb 01; 69(2):168-74. PubMed ID: 22500372
    [Abstract] [Full Text] [Related]

  • 17. Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations.
    Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Çelik AF, Fortune F, Gaudric J, Gul A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G.
    Rheumatology (Oxford); 2018 Dec 01; 57(12):2200-2212. PubMed ID: 30107448
    [Abstract] [Full Text] [Related]

  • 18. Thalidomide: focus on its employment in rheumatologic diseases.
    Ossandon A, Cassarà EA, Priori R, Valesini G.
    Clin Exp Rheumatol; 2002 Dec 01; 20(5):709-18. PubMed ID: 12412207
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients.
    Desbois AC, Biard L, Addimanda O, Lambert M, Hachulla E, Launay D, Ackermann F, Pérard L, Hot A, Maurier F, Mausservey C, Bernard F, Noel N, Alric L, Mirault T, Cohen F, Boussouar S, Resche-Rigon M, Cacoub P, Saadoun D.
    Clin Immunol; 2018 Dec 01; 197():54-59. PubMed ID: 30125675
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.
    Li R, Li X, Zhou H, Shi Y, Wang F, Wu T, Liang J.
    Front Immunol; 2023 Dec 01; 14():1205046. PubMed ID: 37287984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.